Hims & Hers Health (NYSE:HIMS) Shares Gap Down on Analyst Downgrade

Hims & Hers Health, Inc. (NYSE:HIMS) shares gapped down before the market opened on Monday after Barclays lowered their price target on the stock from $39.00 to $35.00. The stock had previously closed at $33.78, but opened at $32.44. Barclays currently has an overweight rating on the stock. Hims & Hers Health shares last traded at $30.8680, with a volume of 2,716,030 shares.

A number of other equities research analysts have also recently commented on the stock. Citigroup reduced their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Morgan Stanley upped their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a report on Friday, May 22nd. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Canaccord Genuity Group boosted their target price on Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $32.17.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 23,726 shares of Hims & Hers Health stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the transaction, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah M. Autor sold 16,773 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $27.85, for a total transaction of $467,128.05. Following the completion of the transaction, the insider owned 48,961 shares in the company, valued at $1,363,563.85. The trade was a 25.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 186,769 shares of company stock worth $6,035,648. Corporate insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HIMS. Binnacle Investments Inc acquired a new stake in Hims & Hers Health during the third quarter worth $28,000. Versant Capital Management Inc lifted its stake in shares of Hims & Hers Health by 801.2% in the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Hims & Hers Health by 70.0% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the last quarter. Silicon Valley Capital Partners purchased a new position in shares of Hims & Hers Health during the 3rd quarter worth $48,000. Finally, Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 8.0%

The stock has a market capitalization of $7.25 billion, a price-to-earnings ratio of -49.23 and a beta of 2.40. The business has a 50-day moving average of $32.37 and a 200-day moving average of $26.14. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same period last year, the business earned $0.17 EPS. The company’s quarterly revenue was up 38.2% compared to the same quarter last year. On average, sell-side analysts expect that Hims & Hers Health, Inc. will post -0.14 EPS for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.